Propofol sequestration within the extracorporeal circuit
Authors:
- 1 July 1994
- journal article
- Published by Springer Nature in Canadian Journal of Anesthesia/Journal canadien d'anesthésie
- Vol. 41 (7) , 583-588
Abstract
Various drugs administered during cardiac anaesthesia are sequestered in the extracorporeal circuit in vitro, but it is uncertain whether this sequestration phenomenon affects plasma drug concentration in vivo. The present study was undertaken to evaluate (1) in vitro sequestration of propofol in the extracorporeal circuit and (2) whether the change in plasma propofol concentration induced by initiation of cardiopulmonary bypass in vivo can be explained by haemodilution. For the in vitro evaluation, three separate experiments with a closed circuit (membrane oxygenator, reservoir, and tubings) were performed. The pH and PCO2 of the circulating solution (a mixture of Ringer’s acetate and whole blood) were maintained within the normal physiological range, and the temperature of the solution was 28° C. The solution was circulated at a flow of 4 L · min−1 and propofol was added to the solution to achieve a concentration of 2 μg · ml−1. Serial samples were taken from the circulating solution for measurement of propofol concentration by high performance liquid chromatography. In the in vivo part of the study, 14 patients received a continuous infusion of propofol, and samples for the determination of plasma propofol concentration and blood haematocrit were taken before and five and ten minutes after initiation of cardiopulmonary bypass. In vitro, at 5 and 120 min after addition of propofol into the circulating solution, approximately 65% and 25%, respectively, of the predicted propofol level was measurable in the solution. In vivo, five minutes after initiation of the cardiopulmonary bypass plasma propofol concentration decreased (P < 0.001) more (from 2.8 ±0.7 (mean ± SD) to 1.5 ± 0.5 μg · ml−1, a 45 ± 12% decrease) than would have been predicted on the basis of acute haemodilution (a decrease in haematocrit from 0.39 ± 0.04 to 0.28 ± 0.03 is a 29 ± 4% decrease). Ten minutes after initiation of cardiopulmonary bypass, plasma propofol concentration was 1.6 ± 0.5 μg · ml−1 (a 37 ± 27% decrease from the pre-bypass level) and haematocrit was 0.27 ± 0.04 (a 30 ± 6% decrease): the decrease in plasma propofol concentration was not different from the decrease observed in the haematocrit. In conclusion, propofol is markedly sequestered within the extracorporeal circuit in vitro. This sequestration may, to some extent, affect plasma propofol concentration in vivo. Cette étude vise à déterminer I) l’importance de la séquestration in vitro du propofol dans le circuit de circulation extracorporelle (CEC) et 2) si l’hémodilution seule peut expliquer in vivo les changements de concentration plasmatique qui surviennent après l’initiation de la CEC. Pour l’étude in vitro, trois expériences en circuit fermé séparées (oxygénateur à membrane, réservoir et tubulures) sont effectuées. Le pH et la PCO2 de la solution circulée sont maintenus dans les limites de la normale physiologique avec une température de 28° C. La solution circule avec un débit de 4 L · min−1 et du propofol est ajouté à la solution pour obtenir une concentration de 2 μg · ml−1. Des échantillons en série sont prélevés pour la mesure de la concentration du propofol par Chromatographie en phase liquide à haute performance. Pour l’étude in vivo, 14 patients reçoivent du propofol en perfusion continue et des échantillons sont prélevés pour déterminer la concentration plasmatique de propofol et l’hématocrite à cinq et dix minutes après le début de la CEC. In vitro, à 5 et 120 min après l’ajout du propofol dans la solution circulée, environ 65% et 25% respectivement du niveau de propofol prédit sont mesurables dans la solution. In vivo, cinq minutes après l’initiation de la CEC, la concentration plasmatique de propofol diminue (P < 0,001) à un degré plus considérable (de 2,8 ± 0,7 moyenne ± SD à 1,5 ± 0.5 μg · ml−1, une baisse de 45 ± 12%) qu’on pouvait le prédire sur la base de l’hémodilution aiguë (une baisse de l’hématocrite de 0,39 ± 0,04 à 0,28 ± 0,03, soit une baisse de 29 ± 4%). Dix minutes après l’initiation de la CEC, la concentration plasmatique de propofol est de 1,6 ± 0,5 μg · ml−1 (une baisse de 37 ± 27% du niveau pré-CEC) et l’hématocrite se situe à 0,27 ± 0,04 (une baisse de 30 ± 6%); la baisse de la concentration plasmatique de propofol n’est pas différente de la baisse de l’hématocrite. En conclusion, la séquestration in vitro du propofol dans le circuit de CEC est considérable. Cette séquestration peut affecter jusqu’à un certain point la concentration de propofol in vivo.Keywords
This publication has 18 references indexed in Scilit:
- Anaesthesia for myocardial revascularisationAnaesthesia, 1992
- The pharmacokinetics of propofol in laboratory animalsXenobiotica, 1992
- A comparison of the myocardial metabolic and haemodynamic changes produced by propofol-sufentanil and enflurane-sufentanil anaesthesia for patients having coronary artery bypass graft surgeryCanadian Journal of Anesthesia/Journal canadien d'anesthésie, 1991
- Thiopentone pharmacokinetics during cardiopulmonary bypass with a nonpulsatile or pulsatile flowActa Anaesthesiologica Scandinavica, 1989
- Cardiopulmonary Bypass and the Pharmacokinetics of DrugsClinical Pharmacokinetics, 1989
- Propofol—fentanyl anaesthesia for coronary artery surgery and cardiopulmonary bypassAnaesthesia, 1989
- Binding of fentanyl and alfentanil to the extracorporeal circuitActa Anaesthesiologica Scandinavica, 1987
- Thiopentone levels during cardiopulmonary bypassAnaesthesia, 1986
- Loss of nitroglycerin to cardiopulmonary bypass apparatusCritical Care Medicine, 1983
- Administration of drugs during cardiopulmonary bypassAnaesthesia, 1980